Meningococcal vaccine

Global Adult Vaccines Market Research Report 2023: Market to Surpass $25 Billion by 2027 - Long-term Forecasts to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 11, 2023
Health, Pharmaceutical, Measles, DPT, Research report, Hepatitis, COVID-19, Hospital, Acquisition, Food, Vaccine, Tuberculosis, Traction, Prevalence, Meningococcal vaccine, GSK plc, SARS, Infection, World Health Organization's response to the COVID-19 pandemic, Simplex, World Health Organization, Shingles, Merck, Growth, Statistics, Lonrho, Merck & Co., Tetanus, Regulation of tobacco by the U.S. Food and Drug Administration, Sanofi, Messenger, Streptococcus, Research, Themis

Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.

Key Points: 
  • Various technologies are harnessed to develop these vaccines, encompassing live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines.
  • The adult vaccines market research report is an invaluable resource, offering a wealth of statistics on the adult vaccines market, including global market size, regional distributions, insights into market competitors with their respective market shares, comprehensive segmentation of the adult vaccines market, prevailing market trends, and promising opportunities.
  • These alarming statistics underscore the pivotal role of adult vaccines in curbing the spread of contagious diseases and substantiate the burgeoning growth of the adult vaccines market.
  • The adult vaccines market encompasses the sales of mRNA vaccines and viral vector vaccines.

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

Retrieved on: 
Friday, August 25, 2023
Other Health, Research, General Health, Professional Services, Pharmaceutical, Oncology, Healthcare Reform, Science, Legal, Congressional News, Views, Health, Public Policy, Government, Orphan Drug Act of 1983, Eculizumab, REMS, Central nervous system, Drug development, Vaccination, Prostate cancer, GMG, Infection, Attenuated vaccine, Fever, JAMA, Cancer, Light, Neuromyelitis optica spectrum disorder, Breast, Medicine, NMOSD, IRA, AstraZeneca, Rash, American Medical Association, Neisseria meningitidis, Vomiting, Inflation, ODA, Low-probability-of-intercept radar, Meningococcal vaccine, Patient, Risk, Autoimmune disease, PNH, Immune system, Nausea, Confusion, Inflation Reduction Act of 2022, Rare, Headache, Patient safety, Death, Disease, Pharmaceutical industry, Vaccine

To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).

Key Points: 
  • To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).
  • Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Rare disease and cancer patients depend upon high-risk, low-probability drug development that takes many years to develop and aims for cure.
  • One example is LYNPARZA® (olaparib), a small-molecule cancer medicine approved in 2014 in the US for a small group of late-line ovarian cancer patients.
  • Additional trials added small groups of breast and pancreatic cancer patients, with the most recent indication in prostate cancer approved just this year – nine years later.

Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

Retrieved on: 
Thursday, June 29, 2023
Vaccine, Streptococcus, Life, Public, Meningococcal vaccine, Acne, Play, Messenger, Science, Respiratory syncytial virus, RSV, Machine learning, Metapneumovirus, Sanofi, Growth, FDA, Glass, Meningitis, Disease, Pharmaceutical industry

Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

Key Points: 
  • Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
    Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030, fueled by an accelerated pace of innovation
    Paris, June 29, 2023.
  • Today Sanofi is hosting a Vaccines Investor Event dedicated to its pipeline with key members of its leadership team.
  • Global Head of Vaccines R&D, Sanofi
    “With the addition of mRNA, we now have the largest development toolbox in the industry.
  • Adding machine learning and antigen design means that our future vaccines will raise the bar beyond today’s high standards.

Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023

Retrieved on: 
Thursday, March 2, 2023
Research, Neurology, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Immune system, GMG, Vaccination, STEC-HUS, Hemolytic–uremic syndrome, Death, Shiga toxin, Acetylcholine receptor, REMS, Syndrome, Neisseria meningitidis, Nausea, Confusion, Attenuated vaccine, Fever, Rash, Risk, Medicine, Meningococcal vaccine, Chelsea Handler, Infection, Vomiting, Disease, Light, Patient safety, Headache, Pharmaceutical industry, Vaccine

ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Key Points: 
  • ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
  • It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age.
  • It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children.
  • Your healthcare provider will give you a Patient Safety Card about the risk of meningococcal infection.

February 23 is National Kids and Vaccines Day

Retrieved on: 
Tuesday, February 7, 2023
Public Health Ontario, Caregiver, Organization, Canadian Medical Association, Science, Infection, CHC, Vaccine, HPV, Vaccination, Safety, Measles, Parent, The Honourable, Meningococcal vaccine, Health care, Public health, ScienceUpFirst, Public, COVID-19, Social media, National Kid, Hepatitis B, Pharmaceutical industry, Child

TORONTO, Feb. 7, 2023 /CNW/ - Building on the success of the first Kids and Vaccines Day in 2022, Children's Healthcare Canada (CHC) and ScienceUpFirst have declared February 23, 2023 as National Kids and Vaccines Day 2023.

Key Points: 
  • TORONTO, Feb. 7, 2023 /CNW/ - Building on the success of the first Kids and Vaccines Day in 2022, Children's Healthcare Canada (CHC) and ScienceUpFirst have declared February 23, 2023 as National Kids and Vaccines Day 2023.
  • To bring attention to the day, ScienceUpFirst and Children's Healthcare Canada will host a free national Kids and Vaccines Town Hall event on Thursday, February 23 at 5 pm pst/8 pm est/9 pm ast.
  • "Congratulations, Children's Healthcare Canada and ScienceUpFirst in delivering the second National Kids and Vaccines Day to promote the importance of routine vaccination.
  • "Children's Healthcare Canada is proud to partner with ScienceUpFirst to host the second annual National Kids and Vaccines Day, on February 23, 2023.

Outlook on the Meningococcal Vaccines Global Market to 2030 - Increasing Immunization Programs and Government Initiatives is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Infectious Diseases, Pharmaceutical, Health, Inactivated vaccine, Sanofi, Goal, NIP, ECDC, Meningitis Vaccine Project, Disease, Government, National Center for Immunization and Respiratory Diseases, Organization, WHO, Meningitis, MenAfriVac, Vaccine, FDA, Growth, Profile, Meningococcal disease, Incidence, Prevalence, Epidemic, CAGR, USD, Pharmaceutical industry, Meningococcal vaccine, Meningococcal vaccine, Serotype, EU, Meningococcal vaccine

The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.

Key Points: 
  • The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.
  • In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth.
  • The increase in approval of novel vaccines is expected to improve meningococcal prevention which in turn, is anticipated to drive the market.
  • Initiatives undertaken by the government to combat the rising incidence of the disease are anticipated to boost the meningococcal vaccine market growth.

Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

Retrieved on: 
Wednesday, December 1, 2021
Infant, Capital market, Meningitis, Meningococcal vaccine, Center of excellence, Booster, Woman, Health, Infertility, Program, Vaccine, Chlamydia, History, Pain, EST, Center, CET, Sanofi–Translate Bio COVID-19 vaccine, Risk, Acne, RNA transfection, RSV, Respiratory syncytial virus, Public health, Science, Infection, Webcast, Immunotherapy, Disease, Growth, Sanofi Pasteur, Pharmaceutical industry

Sanofi confirms its mid-term sales guidance announced at the 2019 Capital Markets Day of mid-to-high single-digit growth1 for its Vaccines business.

Key Points: 
  • Sanofi confirms its mid-term sales guidance announced at the 2019 Capital Markets Day of mid-to-high single-digit growth1 for its Vaccines business.
  • These core franchises are well positioned to capture market growth, such as in the global influenza market which Sanofi expects to exceed 15 billion by 20304.
  • Equipped with this set of expertise, we are best positioned to deliver innovative vaccines designed to combat endemic and epidemic infectious diseases.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Travel Advisory - REMINDER - On July 5th, fully vaccinated travellers eligible to enter Canada can benefit from reduced public health measures

Retrieved on: 
Friday, July 2, 2021
Medical specialties, Health, Medicine, Vaccines, Passports, Prevention, Quarantine, Tropical diseases, International Certificate of Vaccination or Prophylaxis, Meningococcal vaccine

It is important to note that travellers arriving before 12:01 a.m. EDT on July 5th will not be eligible for the reduced public health measures.

Key Points: 
  • It is important to note that travellers arriving before 12:01 a.m. EDT on July 5th will not be eligible for the reduced public health measures.
  • This means that travellers who have recently returned to Canada must continue and complete their 14-day quarantine and day 8 test.
  • These changes are only applicable to fully vaccinated travellers who are currently eligible to enter Canada.
  • To benefit from the reduced public health measures, travellers must:
    Be fully vaccinated : To be considered fully vaccinated, a traveller must have received the full series of a vaccine or combination of vaccines accepted by the Government of Canada at least 14 days prior to entering Canada.

Global Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024: Assessment, Future Trends, Unmet Needs, Marketed Vaccines

Retrieved on: 
Monday, March 15, 2021
Vaccines, Medical specialties, Health care, Health, Vaccine, Pentavalent vaccine, Meningococcal vaccine, Pfizer

DUBLIN, March 15, 2021 /PRNewswire/ -- The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 15, 2021 /PRNewswire/ -- The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of GlaxoSmithKline's and Pfizer's pentavalent vaccines in H2 2023 and H1 2024, respectively.
  • The five major European markets (France, Germany, Italy, Spain, and the UK) are expected to experience anemic growth over the forecast period because pentavalent vaccines have much lesser appeal within the EU.
  • Thus, with compelling immunogenicity data in both of the key market segments for MenACWY vaccines, MenQuadfi is expected to erode the market shares of both incumbents.

Global Meningococcal Vaccines Disease Forecast and Market Analysis Report 2021-2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Health, General Health, Vaccines, Medical specialties, Health care, Medicine, Vaccination, Hepatitis B, Diphtheria, Pentavalent vaccine, Tetanus, Meningococcal vaccine, Vaccine, Pfizer

The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The five major European markets (France, Germany, Italy, Spain, and the UK) are expected to experience anemic growth over the forecast period because pentavalent vaccines have much lesser appeal within the EU.
  • Thus, with compelling immunogenicity data in both of the key market segments for MenACWY vaccines, MenQuadfi is expected to erode the market shares of both incumbents.
  • GlaxoSmithKline and Pfizer are both developing pentavalent vaccines, MenABCWY and PF-06886992, respectively, which aim to partially or completely replace separate MenACWY and MenB vaccines for adolescents in the lucrative US market.